In the year ended 31 December 2024, Biodexa did not generate any gross revenue
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biotech Alert: Searches spiking for these stocks today
- 3 Penny Stocks to Watch Now, 3/20/25
- Biodexa says on track to initiate Phase 3 trial in FAP next quarter
- Biodexa Pharmaceuticals Advances Phase 3 eRapa Program with FDA Approval
- Biodexa Pharmaceuticals announces outcome of a Type C meeting with FDA on eRapa
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue